Seven Fleet Capital Management LP Acquires 196,882 Shares of Avalo Therapeutics, Inc. $AVTX

Seven Fleet Capital Management LP boosted its holdings in shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) by 34.3% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 770,765 shares of the company’s stock after purchasing an additional 196,882 shares during the period. Avalo Therapeutics accounts for approximately 2.4% of Seven Fleet Capital Management LP’s portfolio, making the stock its 8th biggest position. Seven Fleet Capital Management LP’s holdings in Avalo Therapeutics were worth $14,244,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in AVTX. Dimensional Fund Advisors LP acquired a new stake in shares of Avalo Therapeutics during the third quarter worth about $143,000. Boothbay Fund Management LLC acquired a new position in shares of Avalo Therapeutics in the 2nd quarter valued at approximately $56,000. AlphaCentric Advisors LLC acquired a new position in shares of Avalo Therapeutics in the 1st quarter valued at approximately $174,000. Jump Financial LLC acquired a new position in shares of Avalo Therapeutics in the 4th quarter valued at approximately $238,000. Finally, Persistent Asset Partners Ltd bought a new stake in Avalo Therapeutics during the 4th quarter worth approximately $274,000. 87.06% of the stock is owned by institutional investors and hedge funds.

Avalo Therapeutics Stock Performance

NASDAQ AVTX opened at $19.23 on Friday. The stock has a market capitalization of $1.03 billion, a price-to-earnings ratio of -4.40 and a beta of 0.78. Avalo Therapeutics, Inc. has a 52 week low of $9.54 and a 52 week high of $24.27. The stock’s 50 day moving average price is $19.12 and its two-hundred day moving average price is $16.94.

Avalo Therapeutics (NASDAQ:AVTX) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.25). On average, equities research analysts forecast that Avalo Therapeutics, Inc. will post -2.59 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have commented on AVTX shares. BTIG Research restated a “buy” rating and set a $58.00 target price on shares of Avalo Therapeutics in a report on Tuesday, June 16th. Weiss Ratings raised shares of Avalo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Wedbush dropped their price objective on shares of Avalo Therapeutics from $40.00 to $34.00 and set an “outperform” rating on the stock in a report on Thursday, May 14th. Piper Sandler reaffirmed an “overweight” rating and issued a $60.00 price objective (up from $48.00) on shares of Avalo Therapeutics in a research report on Monday, May 11th. Finally, Citizens Jmp reduced their target price on shares of Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating for the company in a research note on Thursday, May 14th. Twelve equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Avalo Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $45.10.

Insiders Place Their Bets

In other Avalo Therapeutics news, insider Mittie Doyle sold 1,450 shares of Avalo Therapeutics stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $18.00, for a total value of $26,100.00. Following the sale, the insider directly owned 51,776 shares in the company, valued at approximately $931,968. The trade was a 2.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 3,129 shares of company stock valued at $59,680 over the last ninety days. 4.46% of the stock is currently owned by company insiders.

Avalo Therapeutics Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.